PTGX
Protagonist Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.51B
P/E Ratio
—
EPS
$-2.05
Beta
2.11
52W High
$107.84
52W Low
$41.10
50-Day MA
$90.99
200-Day MA
$75.11
Dividend Yield
—
Profit Margin
-282.80%
Forward P/E
24.81
PEG Ratio
0.00
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Fundamentals
| Revenue (TTM) | $46.02M |
| Gross Profit (TTM) | $46.02M |
| EBITDA | $-156.85M |
| Operating Margin | -677.00% |
| Return on Equity | -20.20% |
| Return on Assets | -14.00% |
| Revenue/Share (TTM) | $0.72 |
| Book Value | $9.82 |
| Price-to-Book | 10.77 |
| Price-to-Sales (TTM) | 141.56 |
| EV/Revenue | 131.8 |
| EV/EBITDA | 244.64 |
| Quarterly Earnings Growth (YoY) | 351.30% |
| Quarterly Revenue Growth (YoY) | -95.60% |
| Shares Outstanding | $63.81M |
| Float | $51.90M |
| % Insiders | 1.23% |
| % Institutions | 113.69% |
Analyst Ratings
Consensus ($112.42 target)
3
Strong Buy8
Buy1
HoldData last updated: 4/9/2026